DR Tariq

Management of Psoriasis in special
circumstances
Prof Tariq Rashid

Dermatology Department
AIMC/Jinnah Hospital
Lahore
Clinical scenario 1
• Management concerns in
patients who are Hepatitis B
and C positive
Concerns regarding
systemic therapy
- Direct Hepatotoxic effects

- Reactivation
Systemic Options
• Acetretin
• Cyclosporin
• Aprelimast
• Biologics
Acitretin
- Not an immunosuppressant, so no
report on reactivation.
- Patients may be more susceptible to

mild hepatotoxic effects of Acitretin.
- Can be used if no alternative with close

monitoring
Cyclosporin
Possibility of reactivation of HBV.
- Initiation of antiviral therapy recommended
before starting cyclosporin by hepatologist
- Close monitoring for viral load and LFTs
Suppressive effects on reactivation of HCV.

- May be tolerated with close monitoring
Biologics
TNF-alfa inhibitors
• HBV
- Not hepatotoxic
- Reactivation of HBV major risk
• HCV
- TNF-alfa inhibitors may be tolerated
- Etanercept improved clearing of HCV in
a study
Ustekinumab, Secukinomab,
ixekizumab, brodalumab
- Long term data has not shown
increase risk of reactivation of HBV
and HCV.
- Not Hepatotoxic
Aprelimast
• Not Hepatotoxic
• Risk of reactivation low
• Preferred Systemic therapy
Methotrexate
- Reactivation of Virus causing
Fulminant liver failure
- Hepatotoxic
- Should not be prescribed
Clinical scenario 2
• Management of
Psoriasis in HIV
patients
Coordinated care dermatologist
and infectious disease specialist
• Antiretroviral drugs along with

- Phototherapy with Topicals
- Acitretin with Topicals
- Aprelimast with Topicals
- Secukinumab with Topicals
Less favourable options
• Cyclosporine
• Methotrexate
• Biologics (TNF alfa Blockers, ustekinumab)
• Only for refractory cases

• Use cautiously
• Status of HIV be monitored closely
Clinical scenario 3
• Management concerns in
patients with Latent
Tuberculosis
Special concerns
- Immunosuppressive treatment
- Biologics (TNF Blockers), methotrexate ,

cyclosporin may result in reactivation
of TB so screening for TB is
recommended before starting these.
Biologics in Latent Tuberculosis
• Full course of prophylactic TB can be
completed before initiating biologics
• Initiation of Biologic treatment after

one month of ATT treatment and
then continue with both biologics
and ATT.
Preferred treatment in
tuberculosis
• Phototherapy
• Acitretin
• Aprelimast
• Secukinumab
Clinical scenario 4
• Psoriasis and malignancy
Psoriasis and malignancy
• Immunosuppressive effects of systemic

therapies are major safety concern in
patients with history of internal
malignancy
• Best approach depends upon severity of

psoriasis and type of malignancy
• Methotrexate and cyclosporin may
increase the risk for lymphoproliferative
disorders
• TNF-Alfa inhibitors , ustekinumab,

Aprelimast do not appear to increase
risk for internal malignancy
• Phototherapy and acitretin are safe
options
• In Patients with history of melanoma

or non melanoma skin cancers
phototherapy is contraindicated
Clinical scenario 5
• Psoriasis in elderly
Concerns
• Many medical, social, and economic
Comorbidities
• More attention to holistic care
• Increase risk of Adverse drug reactions
• Increase risk of Drug interactions

Concerns
• Topicals and Phototherapy preferred
• Biologics
• Extra care in use of cyclosporin

methotrexate and acitretin due to lower
therapeutic index in elderly
Clinical scenario 6
• Management issues of
Childhood Psoriasis
Childhood Psoriasis
Need for Systemic Therapy
• BSA >20% , erythrodermic, pustular,

arthropathy , localized resistant,
severe psychologic morbidity
Systemic Therapies
• Methotrexate: Preferred therapy
• Cyclosporin: Improvement rapid.

Duration should be limited
• Acitretin: Less effective for plaque

psoriasis
Biologics
• Etanercept : (At least 4 years of age)
• Ustekinumab: ( At least 12 years of age)

• Serious adverse effects are rare.
Childhood psoriasis
special considerations
• Topical calcineurin inhibitors for face and
intertriginous areas
• Vitamin D analogues alone or

combination with low to mid potency
steroids
Childhood psoriasis
• Oral Antibiotics
• Tonsillectomy
• Increased BSA in relation to weight
• Immature status of kidney and liver
Childhood psoriasis
• Active hematopoietic system
• Poor adherence to therapy
• Peer pressure
• Lifestyle modification
Clinical scenario 7
• Management of Psoriasis
during pregnancy
Psoriasis during pregnancy
NB UVB: Safe and effective if feasible
Exacerbation of melasma: Potential risk

Systemic therapy
- Cyclosporin
- TNF Blockers
Cyclosporin
• FDA category C
Risks
• Premature labour
• Low birth weight new born

Biologics
• Anti TNF (category B)
• May be used safely
• Adalimubab , etanercept ,infliximab cross
placenta
• Drug discontinuation suggested at 30
weeks gestation
• Live vaccine to infant postponed till 7th
months of age
Systemic therapy
Systemic steroids only in

Pustular psoriasis of
pregnancy.
Contraindicated therapies
• Tazarotene category x
• Methotrexate category x
• Acetretin category x
• Topical calcineurin inhibitors ( category C)
• Coal Tar (Category C)

• Calcipotriol (Category C)
• Anthralin risks unknown
• PUVA (category C)
• Sulfasalazine (Category B)
• Ustekinumab ( Category B)
• Interleukin 17 inhibitors and aprelimast
(no published reports)
• Fumaric acid esters ( Limited data)
Psoriasis and pregnancy
• Better to plan pregnancy when in remission
• Methotrexate: 3 months interval for both

men and women after stopping the drug
• Acitretin: 3 years interval for women. No

precaution for men
Take Whom Message
for managing psoriatic patients in
special circumstances
• Evaluating the patient for comorbidities

and thorough understanding of risks,
benefits, drug interactions and
contraindications of treatment modalities
is of utmost important.
A N K YO U
TH

DR Tariq

Uploaded by

Copyright:

Available Formats

DR Tariq

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

DR Tariq

Uploaded by

Copyright:

Available Formats

Management of Psoriasis in special

Prof Tariq Rashid

- Direct Hepatotoxic effects

- Patients may be more susceptible to

- Can be used if no alternative with close

Suppressive effects on reactivation of HCV.

• Antiretroviral drugs along with

• Only for refractory cases

- Biologics (TNF Blockers), methotrexate ,

• Initiation of Biologic treatment after

• Immunosuppressive effects of systemic

• Best approach depends upon severity of

• TNF-Alfa inhibitors , ustekinumab,

• In Patients with history of melanoma

• Increase risk of Adverse drug reactions

• Increase risk of Drug interactions

• Extra care in use of cyclosporin

• BSA >20% , erythrodermic, pustular,

• Cyclosporin: Improvement rapid.

• Acitretin: Less effective for plaque

• Ustekinumab: ( At least 12 years of age)

• Vitamin D analogues alone or

Exacerbation of melasma: Potential risk

• Low birth weight new born

Systemic steroids only in

• Coal Tar (Category C)

• Methotrexate: 3 months interval for both

• Acitretin: 3 years interval for women. No

• Evaluating the patient for comorbidities

You might also like